
Director Adult BMT&Cell Therapy Program at Columbia University Irving Medical Center/NYP. Passionate about #SickleCell Transplant and #GVHD. Tweets are mine.
New York City
Joined January 2013
- Tweets856
- Following529
- Followers504
- Likes2.1K
Markus Y. Mapara 🇺🇦 retweeted
A milestone for κ-AL!! Japan approved anselamimab on Sept 16, following Ph III data showing a 62% reduction in mortality κ pt. We hope @FDA and @EMA_News will follow. Patients with rare, life-threatening diseases deserve hope and access to lifesaving treatment #amyloidosis @Amyloidosis_ASB @Amyloidosisfdn @Amyloid_Planet @AmyloidosisSupp @Amyloidosis_ARC
Original Article: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease (BEACON study) nejm.org/doi/full/10.1056/NE…
Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.1056/NE…
Further reading:
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) nejm.org/doi/full/10.1056/NE…
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia (EdiThal study) nejm.org/doi/full/10.1056/NE…
#Hematology #Genetics
Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) nejm.org/doi/full/10.1056/NE…
Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.1056/NE…
Further reading:
📄 Original Article: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease (BEACON study) nejm.org/doi/full/10.1056/NE…
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia (EdiThal study) nejm.org/doi/full/10.1056/NE…

ALT Panel A: A graph of the changes from baseline in the mean total hemoglobin (Hb) level and the percentage of sickle hemoglobin (HbS) and fetal hemoglobin (HbF) among 13 male patients and 15 female patients. Panel B: A graph of the change from baseline in the percentage of F cells (erythrocytes expressing HbF). Panel C: A graph of allelic editing in bone marrow–derived CD34+ cells and peripheral-blood nucleated cells (PBNCs).
In the EdiThal study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia. Full study results: nejm.org/doi/full/10.1056/NE…
Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.1056/NE…
Further reading:
📄 Original Article: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease (BEACON study) nejm.org/doi/full/10.1056/NE…
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) nejm.org/doi/full/10.1056/NE…
In the RUBY study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat sickle cell disease. Full study results: nejm.org/doi/full/10.1056/NE…
Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.1056/NE…
Further reading:
📄 Original Article: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease (BEACON study) nejm.org/doi/full/10.1056/NE…
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia (EdiThal study) nejm.org/doi/full/10.1056/NE…
In the BEACON study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. Full study results: nejm.org/doi/full/10.1056/NE…
Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.1056/NE…
Further reading:
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) nejm.org/doi/full/10.1056/NE…
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia (EdiThal study) nejm.org/doi/full/10.1056/NE…
Wonderful essay by @SLentzsch and Paul Mapara just published in @TheFP @ElishaWiesel #HolocaustMemorialday thefp.com/p/i-was-elie-wiese…
Markus Y. Mapara 🇺🇦 retweeted
TODAY‼️Be there or be square🤓
Markus Y. Mapara 🇺🇦 retweeted
Eliza O'Reilly has an excellent (developing) body of work on randomized decision trees and forests. Here is one of the earlier works.
arxiv.org/abs/2407.02458
🚨 new@ASH_hematology heme talks podcast with Dr Shalini Shenoy @WUSTL on BMT and 🧬 therapy options in Sickle Cell Disease. @nyphospital @Columbia podcasts.apple.com/us/podcas…
Markus Y. Mapara 🇺🇦 retweeted
Replying to @JingFu_PhD
@JingFu_PhD presenting fascinating data from the @SLentzsch and @BMT_updates Laboratories on the production and in vitro/in vivo performance of #ALamyloidosis targeted CAR-phagocytes!!! Game changing antifibril therapies in development @columbiacancer
Markus Y. Mapara 🇺🇦 retweeted
#OnThisDay in 1989, the Berlin Wall fell, marking the end of a divided Germany. 35 years later, we remember the brave citizens of the former GDR who stood up for their freedom. We also remember the critical role that the US played in German Reunification. Thank you, USA! 🇩🇪🇺🇸
Markus Y. Mapara 🇺🇦 retweeted
Have you ever thought about undergoing a bone marrow transplant (BMT) to treat #sicklecell disease (SCD)? 🤔Here are three facts you should know about BMT for SCD.
#SickleCell101 #BoneMarrowTransplant #SickleCellAwareness
Markus Y. Mapara 🇺🇦 retweeted
🚨Breaking News/Good News from #ASH24🚨
>90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in @BMTCTN 1703! 😱
Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌
ash.confex.com/ash/2024/webp…
#PTCyrules
The best way to deal with #Election2024 anxiety is by attending the @ASTCT 🧬 therapy summit in Boston and listening to a fascinating lecture by @harvardmed Dean George Daley on the promise of hematopoietic gene therapy and learning about the first example of cell therapy
Very nice article about 🧬 therapy activities at @Columbia highlighting progress in ENT by Lawrence Lustig, our BMT team in #sicklecell , cardiology by @MathewMaurer and work by Sam Sternberg’s group. @nyphospital @ColumbiaMed
.@columbiaps faculty are pushing gene therapy into its next phase, successfully treating deafness, sickle cell disease, and cardiac amyloidosis. Learn more about their groundbreaking research in the Fall 2024 issue of Columbia Medicine Magazine.
columbiamed.link/3XKVdoY
9
406
Markus Y. Mapara 🇺🇦 retweeted
Backstage at the Columbia University AL Amyloidosis Symposium, with the formidable lineup of @SLentzsch, @DivayaB, @rajshekharucms, @BMT_updates, Dr Radhakrishnan, and Dr Maurer! @columbiacancer #ALamyloidosis
Markus Y. Mapara 🇺🇦 retweeted
Join us at @CAMPamyloidosis @columbiacancer for a comprehensive update on management if AL Amyloidosis!
@SLentzsch @MathewMaurer
NEXT WEEK: Join us for ‘Recent Advances in the Diagnosis & Treatment of AL #Amyloidosis’ - a virtual conference on November 1, 2024 hosted by Columbia University, Department of Medicine. Info & registration:
eventleaf.com/e/Amyloidosis2…
#NephTwitter #NephX #nephrology #cardiology #WorldAmyloidosisDay2024 #kidney
Learn everything you need to know about AL-Amyloidosis with an all-star team
@SLentzsch @MathewMaurer @jradnephro @rajshekharucms @Columbia
@ASH_hematology @ASTCT @BMT_HP11 @Amyloidosisfdn @IMFmyeloma
THIS WEEK: AL #Amyloidosis (11/1); NEXT WEEK: Update in #HospitalMedicine (11/8); Infections in Hospitalized Patients (11/15) and more... Virtual Programs with video access and ACCME Credits. Registration and info:
ColumbiaMedicineCME.org
#Hospitalist #MedX #MedTwitter #InternalMedicine #InfectionPrevention #Nephrology
6
449






























